UCB/Immunomedics's lupus drug positive in Phase IIb trial
This article was originally published in Scrip
Executive Summary
UCB and Immunomedics's epratuzumab outperformed placebo in a Phase IIb trial of systemic lupus erythematosus (SLE) patients, show top-line results. In keeping with previous expectations, the companies plan to proceed into Phase III development in the second half of 2010.